Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-058086
Filing Date
2025-04-24
Accepted
2025-04-24 16:22:01
Documents
19
Period of Report
2025-04-24

Document Format Files

Seq Description Document Type Size
1 DEF 14A xene-20250424.htm   iXBRL DEF 14A 2231319
2 GRAPHIC img255911440_0.jpg GRAPHIC 240987
3 GRAPHIC img255911440_1.jpg GRAPHIC 240987
4 GRAPHIC img255911440_2.jpg GRAPHIC 274889
5 GRAPHIC img255911440_3.jpg GRAPHIC 268674
6 GRAPHIC img255911440_4.jpg GRAPHIC 242760
7 GRAPHIC img255911440_5.jpg GRAPHIC 126914
  Complete submission text file 0000950170-25-058086.txt   6768651

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT xene-20250424.xsd EX-101.SCH 37292
21 EXTRACTED XBRL INSTANCE DOCUMENT xene-20250424_htm.xml XML 467314
Mailing Address 200 - 3650 GILMORE WAY BURNABY A1 V5G 48W
Business Address 200 - 3650 GILMORE WAY BURNABY A1 V5G 48W (604) 484-3300
Xenon Pharmaceuticals Inc. (Filer) CIK: 0001582313 (see all company filings)

EIN.: 980661854 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36687 | Film No.: 25867658
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)